Synergistic Effect of Stereotactic Radiotherapy Combined with Karelizumab on Patients with Advanced NSCLC

Jiayou Guo, Jiayi Guo, Beibei Cheng, Xingbang Sun, Hongwei Zhang, and Jianxin Ma

Department of Oncology, Lianyungang Oriental Hospital Affiliated to Xuzhou Medical University, Lianyun 222042, China

Correspondence should be addressed to Jianxin Ma; 760020210041@xzhmu.edu.cn

Received 12 November 2021; Revised 22 December 2021; Accepted 3 January 2022; Published 8 March 2022

Academic Editor: Rahim Khan

Copyright © 2022 Jiayou Guo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In this paper, synergistic effects of stereotactic radiotherapy (SRS) combined with karelizumab on the patients with advanced NSCLC have been analyzed through extensive experiments. For this purpose, 100 patients with advanced NSCLC in our hospital from December 2018 to December 2020 were selected and divided into control group and observation group. The control group was treated with SRS, while the observation group was treated with karelizumab at the same time. The data of age, gender, BMI, pathological type, and clinical stage were collected and recorded. After 3 months of treatment, the short-term efficacy of the two groups was evaluated according to RECIST solid tumor efficacy evaluation standard. Fasting venous blood of all patients before and 3 months after treatment was collected. The serum levels of matrix metalloproteinase-9 (MMP-9), cytokeratin 19 fragment (CY211), carcinoembryonic antigen (CEA), and vascular endothelial growth factor (VEGF) were detected by the enzyme-linked immunosorbent assay. The KPS score was used to evaluate the quality of life before and after treatment. The incidence of fatigue, diarrhea, and other adverse reactions were compared between the two groups. The patients were followed up for 3 years, and the survival of all patients was recorded. The total effective rate of the observation group was 50.00% (23/46), which was evidently higher than that (27.78% (15/54)) of the control group ($P < 0.05$). After treatment, the parameters of CY211, MMP-9, VEGF, and CEA in the two groups were evidently lower than those before treatment, and the parameters of CY211, MMP-9, VEGF, and CEA in the observation group were evidently lower than those in the control group after treatment ($P < 0.05$). After treatment, KPS parameters of the two groups were evidently higher than those before treatment, and KPS parameters of the observation group were evidently higher than those of the control group after treatment ($P < 0.05$). The 1-year, 2-year, and 3-year survival rates of the observation group were 95.64% (44/46), 89.13% (41/46), and 80.43% (37/46), respectively, and the 2-year and 3-year survival rates of the observation group were evidently higher than those of the control group ($P < 0.05$). SRS combined with karelizumab in the treatment of patients with advanced NSCLC has good curative effect, can evidently inhibit the angiogenesis and tumor growth and metastasis, can evidently improve the quality of life of patients, has a good synergistic effect, and can be widely used in clinic.

1. Introduction

Lung cancer is a malignant lung tumor with a high incidence worldwide, with rapid disease progression, high mortality, and poor prognosis [1]. Non-small cell lung cancer (NSCLC) has the highest incidence, accounting for more than 80% of lung cancer [2]. Because the early course of lung cancer is hidden, most patients are already in the middle and late stages when they are diagnosed, and the effect of surgical treatment is poor [3]. Radiotherapy is one of the most important treatment methods for MSCLC. With the continuous development of radiological technology in recent years, stereotactic radiotherapy (SRS) has played an important role in the treatment of lung cancer [4]. Nguyen et al. [5] found that SRS had achieved good results in the treatment of stage I lung cancer and early multifocal primary lung cancer. However, the treatment effect of SRS for advanced NSCLC patients is poor, with a high incidence of adverse reactions and poor quality of life of patients. As an important immunosuppressive molecule, programmed cell death protein 1 (PD-1) can inhibit the autoimmune response by inhibiting the function of T lymphocyte and finally achieve the function of preventing the occurrence of autoimmune diseases [6]. Carrelizumab is an antibody to PD-1,
which can block the PD-1 pathway and enhance the body’s antitumor immunity. Marsh et al. [7] found that relizumab was effective in the treatment of solid cancers such as gastric cancer, nasopharyngeal cancer, and liver cancer. In this study, 100 patients with advanced NSCLC admitted to our hospital from December 2018 to December 2020 were taken as the observation objects, to analyze the synergistic effect of SRS combined with carrilizumab in patients with advanced NSCLC.

In this paper, synergistic effects of stereotactic radiotherapy (SRS) combined with karelizumab on patients with advanced NSCLC have been analyzed through extensive experiments. For this purpose, 100 patients with advanced NSCLC in our hospital from December 2018 to December 2020 were selected and divided into the control group and observation group. The control group was treated with SRS, while the observation group was treated with karelizumab at the same time. The data of age, gender, BMI, pathological type, and clinical stage were collected and recorded. After 3 months of treatment, the short-term efficacy of the two groups was evaluated according to RECIST solid tumor efficacy evaluation standard. Fasting venous blood of all patients before and 3 months after treatment was collected. The serum levels of matrix metalloproteinase-9 (MMP-9), cytokeratin 19 fragment (CY211), carcinoembryonic antigen (CEA), and vascular endothelial growth factor (VEGF) were detected by the enzyme-linked immunosorbent assay.

The rest of this paper is arranged as given below.

In subsequent section, the proposed mechanism, i.e., synergistic effects of stereotactic radiotherapy (SRS) combined with karelizumab on the patients with advanced NSCLC, has been described in detail which is followed by extensive analysis of the experimental results and observations. Generalized discussion is provided in the second last section which is followed by an extensive summary of the proposed study.

2. Materials and Methods

2.1. Basic Materials. 100 patients with advanced NSCLC admitted to our hospital from December 2018 to December 2020 were taken as the observation objects.

2.1.1. Inclusion Criteria

(1) All patients were diagnosed with NSCLC by pathological examination, confirmed by cytological and histological examination for three to four stages NSCLC

(2) The serum indicators of the patient, such as white blood cells, neutrophils, and platelets were all in the normal range, and the expected survival time was ≥5 months

(3) The patients and their family members were informed and signed the informed consent

2.1.2. Exclusion Criteria

(1) The patient was allergic to the experimental drug.

(2) The patient’s heart, liver, kidney, and other important organs had serious dysfunction.

(3) The patient was mentally ill and could not cooperate with treatment.

(4) The patient was complicated with other malignancies.

(5) The patient refused the experiment or terminated the experiment for other reasons.

This experiment was approved by the hospital ethics committee.

2.2. Proposed Method. According to treatment methods, they were divided into the control group and observation group. Patients in the control group were treated with SRS, and patients in the observation group were treated with carrilizumab while receiving SRS.

Control group: the control group was asked to be in the supine position with arms crossed, and simulated positioning was carried out by CT with a layer thickness of 5 mm. Treatment range is as follows: the primary tumor and local metastases shown by CT, the displacement of respiratory movement in all directions as the gross tumor target (IGTV), and the planning target area (PTV). Radiological dose: IGTV was given 60 Gy/8F and 105 Gy bioavailable dose (BED), once a day, 5 times a week.

Observation group: the SRS treatment was the same as the control group and received intravenous injection of carrilizumab, 200 mg/time, 28 days as a cycle, and treatment for 3 cycles.

2.3. Observation Index. Clinical information: the data of age, gender, BMI, pathological type, and clinical stage of the two groups were collected and recorded.

Short-term efficacy: CT examination was performed after 3 months of treatment, and the efficacy was evaluated using RECIST solid tumor efficacy evaluation criteria: disease progression (PD): the tumor size increased ≥25% or new lesions were found; no change (SD): the tumor size increased ≥25% or new lesions were found; partial remission (PR): the tumor size of lung cancer decreased ≥50%, duration ≥4 weeks; and complete remission (CR): the tumor tissue of lung cancer disappeared completely, and the duration was ≥4 weeks. Total efficacy = CR + PR.

Sera diagnosis: fasting venous blood from all cases before treatment and 3 months after treatment was collected and placed at room temperature for 20 min, centrifuged at 3000 r/min for 10 min, and put it in −70°C for refrigeration to avoid repeated freeze-thaw. Serum cytokeratin 19 fragment (CY211), vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and carcinoembryonic antigen (CEA) were determined by the enzyme-linked immunosorbent assay.
Karnofsky performance scale (KPS) score was used to analyze the quality of life before and after treatment: KPS scores were obtained before treatment and 3 months after treatment, with a total score of 100. The higher the quality of life, the higher the KPS scores.

Adverse reactions: the incidence of adverse reactions, such as fatigue, diarrhea, pruritus, thrombocytopenia, and neutropenia were recorded and compared between the two groups.

Survival situation: the survival of all patients was recorded, and the follow-up period was 3 years.

2.4. Statistical Method. The data in this study were analyzed by the SPSS20.0 software package, enumeration data such as gender, pathological type, clinical stage, common efficiency of treatment, incidence of adverse reactions, and survival of each subject were expressed as percentage, $\chi^2$ was used for pairwise comparisons, serum CY211, MMP-9, VEGF, and CEA measurement data were expressed as $(\bar{x} \pm s)$, pairwise comparisons were performed using the $t$-test. $P < 0.05$ was considered statistically significant.

3. Experimental Results and Observations

3.1. Comparison of Clinical Data between Two Groups. There was no significant difference in age, gender, pathological type, and clinical stage between two groups ($P > 0.05$). Comparison of clinical data between two groups is shown in Table 1:

3.2. Comparison of Treatment Effect between Two Groups. The total effective rate of the observation group was 50.00% (23/46), which was evidently higher than 27.78% (15/54) of the control group ($P < 0.05$). Comparison of treatment effect between two groups is shown in Table 2:

3.3. Comparison of Serum Indexes between Two Groups. After treatment, the parameters of CY211, MMP-9, VEGF, and CEA in the two groups were evidently lower than those before treatment, and the parameters of CY211, MMP-9, VEGF, and CEA in the observation group were evidently lower than those in the control group after treatment ($P < 0.05$). Comparison of serum indexes between two groups is shown in Table 3:

3.4. Comparison of KPS Parameters of Two Groups. After treatment, KPS parameters of the two groups were evidently higher than those before treatment, and KPS parameters of the observation group were evidently higher than those of the control group after treatment ($P < 0.05$). Comparison of KPS parameters of two groups is shown in Table 4:

3.5. Comparison of Adverse Reactions between Two Groups. The incidence of adverse reactions in the observation group was evidently higher than those in the control group ($P < 0.05$). Comparison of adverse reactions between two groups is shown in Table 5:

3.6. Comparison of Survival between Two Groups. The 1-year, 2-year, and 3-year survival rates of the observation group were 95.64% (44/46), 89.13% (41/46), and 80.43% (37/46), respectively, and the 2-year and 3-year survival rates of the observation group were evidently higher than those of the control group ($P < 0.05$). Comparison of survival between two groups is shown in Table 6:

4. Discussion

The early stage of NSCLC is relatively secretive, unable to attract the attention of patients, and the course of the disease develops rapidly. It is often found in the middle and late stages. The treatment effect is not satisfactory and the patient’s prognosis is poor [8]. SRS has been widely used in the treatment of advanced NSCLC patients with advanced age, poor lung function, and intolerance to surgery due to its advantages of noninvasive, short course of treatment, high target dose, and low peripheral normal tissue dose [9]. However, long-term SRS treatment can lead to different degrees of tolerance, increased incidence of adverse reactions, and poor quality of life in patients. PD-1 antibody has the advantages of long efficacy and few complications and is the focus of tumor immunotherapy related research in recent years. Shankar et al. [10] found that Carrelizumab treatment in advanced NSCLC patients could evidently improve the immune function of patients, which was of great significance in inhibiting the development of the disease. In this experiment, the total effective rate of recent treatment in the observation group was 50.00%, evidently higher than that in the control group (27.78%). The 1-year, 2-year, and 3-year survival rates of the observation group were 95.64%, 89.13%, and 80.43%, respectively. The 2-year and 3-year survival rates were evidently higher than those in the control group. SRS combined with carrilizumab in the treatment of advanced NSCLC patients had a good efficacy, had a good synergistic effect, and was of great significance for the effective treatment of patients.

Cancer metastasis is the main cause of treatment failure in patients with advanced NSCL, and angiogenesis within the tumor plays an important role in cancer metastasis. CY211 is a marker produced during the apoptosis of alveolar epithelial cells. It is obviously highly expressed in lung cancer. The changes in its level reflect the changes in the condition of NSCLC [11]. CEA is evidently overexpressed in serum of patients with colon cancer, breast cancer, lung cancer, and other malignant tumors, and the decrease of its level can indicate the reduction of lung cancer tumor cells [12]. VEGF can induce the formation of new blood vessels of cancer cells and improve the infiltration ability of cancer cells by increasing vascular permeability. Xu et al. [13] found that the detection of VEGF had a certain value in predicting the metastasis of breast cancer cells. MMP-9 is a proteolytic enzyme that can degrade the vascular basement membrane and extracellular matrix components and participate in the...
metastasis of cancer cells. Liu et al. [14] found that MMP-9 could participate in the proliferation, metastasis, and invasion of gastric cancer cells by regulating the changes of VEGF indicators. In this study, after treatment, the levels of serum CY211, MMP-9, VEGF, and CEA in 2 groups were evidently decreased. The levels of serum CY211, MMP-9, VEGF, and CEA in the observation group were evidently lower than those in the control group. SRS combined with carrilizumab can evidently inhibit the formation of new blood vessels and the growth and metastasis of tumors.

Table 1: Comparison of clinical data between two groups (x ± s).

| Indicators               | Control group (n = 54) | Observation group (n = 46) | t/χ² | P value |
|--------------------------|------------------------|---------------------------|------|---------|
| Age                      | 61.68 ± 5.46           | 62.74 ± 6.12              | 0.915| 0.362   |
| Gender                   | Male                   | Female                    | 62.74 ± 6.12              | 0.245| 0.621   |
| BMI                      | 22.01 ± 1.08           |                           | 0.083| 0.281   |
| Pathological type        | Adenocarcinoma         | Squamous carcinoma        | 0.404| 0.817   |
|                          | Squamous adenocarcinoma|                           | 0.083| 0.281   |
| Clinical stage           | IIIa                   | IIIb                      |      |         |
|                          | 6 (11.11%)             | 8 (17.40%)                | 0.881| 0.643   |

Table 2: Comparison of treatment effect between two groups (n, %).

| Groups                   | CR    | PR    | SD    | PD    | Total effective rate |
|--------------------------|-------|-------|-------|-------|-----------------------|
| Control group (n = 54)   | 0 (0.00%) | 15 (27.78%) | 20 (37.03%) | 19 (35.19%) | 15 (27.78%) |
| Observation group (n = 46)| 0 (0.00%) | 23 (50.00%) | 15 (32.61%) | 8 (17.39%)  | 23 (50.00%) |

Table 3: Comparison of serum indexes between two groups (x ± s).

| Indicators   | Control group (n = 54) | Observation group (n = 46) | t    | P value |
|--------------|------------------------|---------------------------|------|---------|
| CY211 Before | 6.23 ± 2.06            | 6.38 ± 3.15               | 0.285| 0.775   |
| After treatment | 3.14 ± 1.85a           | 2.50 ± 0.85a              | 2.159| 0.033   |
| MMP-9 Before | 1856.39 ± 190.46       | 1874.23 ± 184.26          | 0.473| 0.636   |
| After treatment | 1524.39 ± 154.29a     | 1047.34 ± 80.16a          | 36.181| < 0.001 |
| VEGF Before   | 749.68 ± 50.29         | 752.61 ± 54.69            | 0.278| 0.780   |
| After treatment | 469.38 ± 20.49a       | 265.49 ± 31.26a           | 39.090| < 0.001 |
| CEA Before    | 21.95 ± 2.84           | 20.96 ± 3.15              | 1.652| 0.101   |
| After treatment | 15.24 ± 2.41a         | 9.46 ± 1.85a              | 13.270| < 0.001 |

*Compared with before treatment in the same group, P < 0.05.

Table 4: Comparison of KPS parameters of two groups (x ± s).

| Groups                   | KFS Before treatment | After treatment | t    | P value |
|--------------------------|----------------------|-----------------|------|---------|
| Control group (n = 54)   | 61.28 ± 9.41         | 71.46 ± 10.59   | 5.280| < 0.001 |
| Observation group (n = 46)| 60.29 ± 8.46         | 77.58 ± 10.46   | 8.716| < 0.001 |

Table 5: Comparison of adverse reactions between two groups (n, %).

| Groups                   | Fatigue | Diarrhea | Itchy skin | Thrombocytopenia | Neutropenia | Total incidence |
|--------------------------|---------|----------|------------|------------------|-------------|-----------------|
| Control group (n = 54)   | 7 (12.96%) | 3 (5.56%) | 1 (1.85%) | 1 (1.85%) | 0 (0.00%) | 12 (22.22%) |
| Observation group (n = 46)| 8 (17.39%) | 2 (4.35%) | 0 (0.00%) | 3 (6.52%) | 1 (2.17%) | 14 (30.43%) |

*Compared with before treatment in the same group, P < 0.05.
which was similar to the research results of Alidoosti et al. [15].

Extending the life cycle of patients and improving the quality of life of patients are the main clinical treatment principles for patients with advanced NSCLC [16]. KPS is a common score for evaluating the quality of life of patients, and it is widely used in clinical practice [17]. In this study, the KPS level of the observation group was significantly higher than that of the control group after treatment [18]. The adverse reactions of the two groups of patients were not statistically significant. SRS combined with carrelizumab in the treatment of advanced NSCLC was well tolerated and could effectively improve the quality of life of patients.

5. Conclusion and Future Directions

In this paper, synergistic effects of stereotactic radiotherapy (SRS) combined with karelizumab on the patients with advanced NSCLC have been analyzed through extensive experiments. For this purpose, 100 patients with advanced NSCLC in our hospital from December 2018 to December 2020 were selected and divided into the control group and observation group. The control group was treated with SRS, while the observation group was treated with karelizumab at the same time. The data of age, gender, BMI, pathological type, and clinical stage were collected and recorded. After 3 months of treatment, the short-term efficacy of the two groups was evaluated according to RECIST solid tumor efficacy evaluation standard. Fasting venous blood of all patients before and after 3 months after treatment was collected. The serum levels of matrix metalloproteinase-9 (MMP-9), cytokeratin 19 fragment (CY211), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF) were detected by the enzyme-linked immunosorbent assay. In conclusion, SRS combined with karelizumab in the treatment of patients with advanced NSCLC has a good curative effect, can evidently inhibit the angiogenesis and tumor growth and metastasis, can evidently improve the quality of life of patients, and has a good synergistic effect, and can be widely used in clinic.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] L. Ni, P. Xue, C. An et al., “Establishment of normal range for thromboelastography in healthy middle-aged and elderly people of weihai in China,” Journal of Healthcare Engineering, vol. 2021, Article ID 7119779, 11 pages, 2021.
[2] H. Wang, L. Feng, Y. Zheng et al., “LINC00680 promotes the progression of non-small cell lung cancer and functions as a sponge of miR-410-3p to enhance HMGB1 expression,” OncoTargets and Therapy, vol. 13, pp. 8183–8196, 2020.
[3] Q. Wang, J. Liao, Z. He et al., “LHX6 affects erlotinib resistance and migration of EGFR-mutant non-small-cell lung cancer HCC827 cells through suppressing vnt/beta-catenin signaling [corrigendum],” OncoTargets and Therapy, vol. 14, pp. 253–254, 2021.
[4] L. Burgess, S. Chakraborty, and S. Malone, “Effective salvage of recurrent criopharyngioma with fractionated stereotactic radiotherapy,” Radiology Case Reports, vol. 15, no. 10, pp. 1750–1755, 2020.
[5] T. K. Nguyen, A. Sahgal, J. Detsky et al., “Predictors of leptomeningeal disease following hypofractionated stereotactic radiotherapy for intact and resected brain metastases,” Neuro-Oncology, vol. 22, no. 1, pp. 84–93, 2020.
[6] R. Mahn, A. Vogt, P. Kupczyk et al., “Programmed cell death protein 1 (PD-1)-inhibition in hepatocellular carcinoma (HCC): a single center experience,” Scandinavian Journal of Gastroenterology, vol. 55, no. 10, pp. 1057–1062, 2020.
[7] R. L. Marsh, J. A. Kolodney, S. Iyengar et al., “Formation of eruptive cutaneous squamous cell carcinomas after programmed cell death protein-1 blockade,” JAAD Case Reports, vol. 6, no. 5, pp. 390–393, 2020.
[8] M. Yang, H. Ke, and W. Zhou, “LncRNA RMRP promotes cell proliferation and invasion through miR-613/NFAT5 Axis in non-small cell lung cancer,” OncoTargets and Therapy, vol. 13, pp. 8941–8950, 2020.
[9] M. Macerelli, S. Rizzato, M. Giavarra et al., “The impact of prior chemotherapy (PrC) on immunotherapy outcomes in non-small cell lung cancer (NSCLC) patients: real data from a mono-institutional study,” Journal of Clinical Oncology, vol. 38, no. 15, p. e21639, 2020.
[10] S. Shankar, A. V. Louie, W. Andrew et al., “Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK),” International Journal of Radiation Oncology, Biology, Physics, vol. 108, no. 4, pp. 941–949, 2020.
[11] J. G. Taylor, A. Clear, M. Calaminici, and J. G. Gribben, “Programmed cell death protein-1 (PD1) expression in the microenvironment of classical Hodgkin lymphoma is similar between favorable and adverse outcome and does not enrich over serial relapses with conventional chemotherapy,” Haematologica, vol. 104, no. 1, pp. e42–e44, 2019.
[12] C. Huang, B. Wang, Y. Chen, and G. Jin, “Label-free immunoassay of carcinoembryonic antigen by microfluidic channel biosensor based on imaging ellipsometry and its clinic

Table 6: Comparison of survival between two groups (n, %).

| Groups          | 1-year survival rates | 2-year survival rates | 3-year survival rates |
|-----------------|-----------------------|-----------------------|-----------------------|
| Control group   | 52 (96.30%)           | 39 (72.22%)           | 33 (61.11%)           |
| Observation group | 44 (95.65%)           | 41 (89.13%)           | 37 (80.43%)           |
| χ²              | 0.026                 | 4.438                 | 4.416                 |
| P value         | 0.869                 | 0.035                 | 0.036                 |
application,” *Integrated Ferroelectrics*, vol. 209, no. 1, pp. 19–29, 2020.

[13] S. Xu, F. Li, and H. Ruijuan, “Effect of T-lymphoma invasion and metastasis inducible factor 1 on proliferation and migration of breast cancer cells and its mechanism,” *Chinese Journal of Experimental Surgery*, vol. 37, no. 12, pp. 2222–2225, 2020.

[14] J. Liu, C. Hong, and P. Liang, “Mechanisms of ERK-VEGF/MMP-9 signaling pathway and proliferation, metastasis and invasion of gastric cancer cells,” *Modern Digestion & Intervention*, no. 9, pp. 984–988, 2019.

[15] M. Alidoosti, M. Shanaki, A. Mahdavi, and N. Mohammadtaghvaei, “Association between vascular endothelial growth factor plasma levels and rs699947 polymorphism and coronary collateral vessel formation.” *The journal of Tehran Heart Center*, vol. 14, no. 3, pp. 121–127, 2019.

[16] S. Baldacci, V. Avrillon, B. Besse et al., “Lorlatinib for advanced ALK and ROS1+ non-small cell lung cancer (NSCLC): efficacy and treatment sequences in the IFCT-1803 LORLATU expanded access program (EAP) cohort,” *Journal of Clinical Oncology*, vol. 38, no. 15_suppl, 2020.

[17] N. Y. Celtek, S. Mustafa, and D. Osman, O. Ismail, Karnofsky performance scale validity and reliability of Turkish palliative cancer patients,” *Turkish Journal of Medical Sciences*, vol. 49, no. 3, pp. 894–898, 2019.

[18] H. Zhao, C. Wang, F. Yu, and Q. Guo, “Decitabine combined with CAG regimen in the treatment of elderly patients with acute myeloid leukemia,” *Pakistan journal of medical sciences*, vol. 36, no. 2, pp. 141–145, 2020 Jan-Feb.